Local Injection Site Reactions Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, respectively. The most common injection site reactions wereerythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site...
Adverse Reactions in Primary Hyperlipidemia:The most common adverse reactions (>5% of patients treated with Repatha®and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions. ...
The most common side effects of Repatha®include: runny nose, sore throat, symptoms of the common cold, flu or flu-like symptoms, back pain, high blood sugar levels (diabetes) and redness, pain, or bruising at the injection site. ...
The article reports that the Repatha injection, a parenteral proprotein convertase subtilisin kexin type 9 inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the management of hypercholesterolemia inadequately treated with standard lipid-lowering therapy....
• Rotate the injection site with each injection. 3 DOSAGE FORMS AND STRENGTHS REPATHA is a sterile, clear to opalescent, colorless to pale yellow solution available as follows: • Injection: 140 mg/mL solution in a single-use prefilled syringe • Injection: 140 mg/mL solution in a ...
The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, ...
The article offers information on the drug Repatha which is an evolocumab injection. Topics discussed include Repatha being a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor antibody, two trials evaluating role of Repatha in primary hyperlipidemia in patients with clinical ...